Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07064122 | A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) | PHASE1 | RECRUITING | 72 | — | — | Nov 3, 2025 | Oct 20, 2028 | Mar 2, 2026 | 21 | United States, Australia +5 |
A DLT is defined as an adverse event or abnormal laboratory value occurring during the DLT-evaluation period (first 28 days of treatment). This will be evaluated to assess the safety and tolerability and also to identify optimal biological dose (OBD) of AZD2962.
To assess the safety and tolerability of AZD2962 and also to identify OBD of AZD2962.
To assess the safety and tolerability of AZD2962, and also to identify OBD of AZD2962.
To assess the safety and tolerability of AZD2962, and also to identify OBD of AZD2962.
| Arm | Type | Description |
|---|---|---|
| Module 1- AZD2962 (Monotherapy) | EXPERIMENTAL | Participants with MDS and dysplastic CMML will receive AZD2962 as monotherapy in a dose escalation pattern. |
| Name | Type | Description |
|---|---|---|
| AZD2962 | DRUG | AZD2962 will be administered orally once daily. |
Key Inclusion Criteria: 1. Participants with relapsed/refractory MDS or participants with relapsed/refractory dysplastic CMML, with peripheral blasts or bone marrow blasts \< 20%, and who received one or more prior lines of therapy as per standard of care (or who exhausted locally available treatme...